Download Mini-Update - April 2015 - Missouri Cancer Registry

MCR MINI-UPDATE APRIL 2015
Fellow Registrars,
I want to re-affirm how blessed I feel to work with such a professional and dedicated group of
registrars across Missouri. You keep the light burning in the cancer surveillance lighthouse
even when the storm clouds of change threaten. Please know that you are appreciated! I
hope that you find a way to celebrate National Cancer Registrars Week April 6-10. If you are
in the Columbia area, let Shari know If you would like to join MCR for lunch on April 7 at 11:30
at Arris Pizza.
Due Dates
Large hospitals (>500 cases/yr.) are to report Sept 2014 cases by April 15 and smaller facilities (<300
cases /yr.) report the 3nd Quarter of 2014 by April 15.
Education
NAACCR Webinars – Get 3 CEs By Viewing Recorded Webinars. Request Access Now! Check out our
Education and Training page to find out how you can receive access to the recorded NAACCR Webinars.
April 2, 2015 – Collecting Cancer Data: Stomach and Esophagus (Live webcast at MCR)
GoToMeeting - There are only 25 lines available so it will be a first come, first serve on the day of the
meeting. We recommend that if there are several of you from one facility that want to participate in a
meeting you call in as a group. For those of you not familiar with GoToMeeting, you can listen via your
computer speakers or headphones and ask questions via a microphone or type a chat message within
GoToMeeting. If you have to call in to listen you will be charged for a long distance call.
April 8, 2015 – SEER Summary Stage: Colon
Fundamentals of Abstracting Workshop – This day and a half workshop will focus on the MCR Abstract
Code Manual and will give you an opportunity to abstract practices cases. This is a great workshop for
those new to abstracting as well as those that need a refresher course.
April 2-3, 2015 at the Missouri Cancer Registry and Research Center
To register for any of our educational opportunities, call 1-866-240-8809 or contact Shari Ackerman at
[email protected].
CancerCare: Connect Education workshop - These workshops are free – no phone charges apply. You
can listen to leading experts in oncology provide the most up-to-date information on the telephone or
via live streaming. Please feel free to forward to your colleagues or anyone affected by cancer.
These workshops will be taking place from 1:30pm to 2:30pm EST:
April 2, 2015 - Progress in the Treatment of Multiple Myeloma
April 15, 2015 - Emerging Therapies in Hodgkin and T-Cell Lymphomas
April 21, 2015 - Precision Medicine: Implications for the Treatment of Prostate Cancer
April 28, 2015 - Medical Update on Ovarian Cancer
April 29, 2015 - Updates in the Treatment of HER2 Positive Breast Cancer
Part I of Living with Breast Cancer
For more information and to register, visit the CancerCare Website or call 1-800-813-HOPE (4673).
MCR News
2015 Case Reporting
We won’t be able to accept 2015 cases until after we upgrade our systems to NAACCR v15, which is
planned for mid-August. Facilities should hold any 2015 cases until then. If you abstract them while your
hospital software is still in v14, then you may have to touch them again in v15 to clear edits and
complete the newly required field, “Date of Most Definitive Surgery” or its date flag.
New Edits for 2015
Several new edits will be included in your v15 software. Edits will:
 check for blanks in the referred to and referred from fields for applicable classes of case
 check for inappropriate site and histology 8050 pairing
 check that grade for C80.9 solid tumor cases equals 9
 check Gleasons score vs. grade and flag cases dx’d 2014+ that need correction
The Missouri Edits metafile for 2015 cases is due to be sent to vendors this week for incorporation in
your v15 software conversion.
MCR/NPCR vs. SEER Reportability Rules
The fact that the 2015 SEER Manual was recently published has raised some questions from hospital
registrars about discrepancies in casefinding and reportability instructions compared to past MCR
requirements. MCR is not a SEER state, so we do not necessarily follow them. I raised your questions
with our governing body, NPCR, and they are meeting soon to consider whether they will require the
same types of cases. I will email you as soon as I know more because I know you are well into your 2015
casefinding.
In the meantime, I do want to remind you that, as I reported in the April 2014 Monthly Update, there
were some changes made to ICD-O-3 at that time that do affect 2015 cases. I am re-issuing this
reminder and have highlighted the pertinent section below. Carcinoid of the appendix becomes
reportable because of the NAACCR adoption of the change of its behavior to /3. Please continue to use
Tables 1 and 2 in the link below along with your ICD-O-3 Manual when checking casefinding. There have
been no further NAACCR guidelines published on this topic since 4/15/14.
From April 2014 Monthly Update:
ICD-O-3 Update
In Sept. 2011 the WHO published Updates to ICD-O-3 to modernize some terminology. Many of
the updates were not implemented immediately in the US to allow a NAACCR work group time
to evaluate the impact on registries. Their step-wise recommendations for 2014-15 were just
approved. The full implementation guidelines with tables are available from NAACCR at
http://www.naaccr.org/LinkClick.aspx?fileticket=u7d3sB71t5w%3d&tabid=126&mid=466. Your
existing copy of the third edition of ICD-O-3 will continue to be useful when accompanied by
Tables1 & 2 from the implementation guidelines.
For implementation with 2014 diagnoses there are 36 new terms for 22 reportable conditions
(Table 1). They are synonymous with existing terms.
For 2015 reporting, 11 more new terms with new codes will be added (Table 2). Most are rare or
very site-specific. If these terms show up on pathology reports while CSv2.05 is in effect, Table 2
shows which existing codes to use. All carcinoids of the appendix will also become reportable
(/3) then. Enteroglucagonoma histology code will shift from 8157 to 8152.
The work group is still evaluating complex issues surrounding many dysplasias and what the
impact might be if any were to be required at some future date. Also under consideration are
new terms that are expected for bronchiolo-alveolar carcinoma, and interpretation of GIST risk
categories.
Abstracting Tips
Diagnostic Confirmation: the code for hematopoietic primaries diagnosed from peripheral blood is 1 –
Positive Histology. Diagnostic Confirmation code 2 – Positive Cytology is INCORRECT when the diagnosis
is based on results of the peripheral blood smear. See page 14 of the Hematopoietic and Lymphoid
Neoplasm Coding Manual.
Date of 1st Course Treatment: Record the earliest date on which treatment for the reported cancer
began, including active surveillance only, or the date the decision was made not to treat (watchful
waiting or refusal by patient). See page 66 of the MCR Manual.
Unknown treatment: When treatment is truly unknown, code:
Treatment status: 9
Date of first course treatment flag: 10
Various treatments: at least one must = 9 or 99, and the remaining should indicate either unknown if tx
9/99 or no tx (00 or 7-8, or 80-88)
Treatment text should state that you have no information as to whether or not treatment was given.
Standard Setter News
SEER Completes Hematopoietic Conversion Documents for 2015 reporting
The conversion to NAACCR version 15 includes conversion of some hematopoietic codes. Please see the
SEER documentation at: http://seer.cancer.gov/tools/heme/conversion.html
NCRA Announces a New Complimentary Resource: Informational Abstracts
To assist registrars in preparing abstracts, NCRA's Education Committee has created a series of
informational abstracts. These site-specific abstracts provide an outline to follow when determining
what text to include. The sites include: bladder, breast, colon, lung, melanoma, and prostate. The
outline has a specific sequence designed to maximize efficiency. Check out this complimentary
resource!
New CS Transition Newsletter
http://www.ncra-usa.org/files/public/CSTransitionNewsletterIssue(March2015).pdf
Now Available! Second Module of the AJCC Curriculum for Registrars
AJCC Curriculum for Registrars are presentations designed to provide education in a step-wise learning
environment complete with additional resources to reinforce the information and webinars with
interactive quizzes to prompt discussion and serve as a self-assessment for the information learned.
Second module is now available
CAnswer Form Redesigned
Get an overview and tips on navigating it here:
http://newsmanager.commpartners.com/acscoc/issues/2015-03-02/3.html
Cancer Trends Progress Reports redesigned
The National Cancer Institute is pleased to announce the launch of the newly redesigned Cancer Trends
Progress Report. After 14 years, they have given the website a new look and feel to better serve those
looking for national trend data across a spectrum of cancer control measures. From prevention to end
of life, the site offers trends by sex and age, race and ethnicity, and income and education level, and
displays them in relation to Healthy People 2020 targets, where they are available. Visit the site to see
new measures in HPV immunization; cancer survivorship as it relates to physical activity and obesity;
and four new environmental exposures, including arsenic, benzene, cadmium, and nitrate. Please visit
www.progressreport.cancer.gov.
Registry to Research
International trends and variations in renal cell carcinoma incidence and mortality (GLOBOCAN data)
http://www.europeanurology.com/article/S0302-2838%2814%2901010-0/fulltext/internationalvariations-and-trends-in-renal-cell-carcinoma-incidence-and-mortality
Invasive Cancer Incidence and Survival (NPCR and SEER data)
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6409a1.htm?s_cid=mm6409a1_w
http://www.christiantimes.com/article/cancer.survival.rates.2.in.3.cancer.patients.survive.5.years.or.m
ore.prostrate.cancer.patients.have.best.survival.rate.of.97.c.d.c/51561.htm
Cancer Survival in Asian Americans (SEER data)
http://www.medicalnewstoday.com/releases/291413.php?tw
Inequalities in premature death from colorectal cancer by state (CDC data)
http://jco.ascopubs.org/content/33/8/829.full
Colorectal cancer death rates by sex (CDC data)
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6411a6.htm?s_cid=mm6411a6_w
Death rates rising for liver cancer, falling for colorectal (SEER data)
http://www.practiceupdate.com/c/22367/2/1/?elsca1=emc_enews_dailydigest&elsca2=email&elsca3=practiceupdate_onc&elsca4=oncology&elsca5=newsletter&rid=NTU2MjE4
MTE1NjYS1&lid=10332481
Hormone receptor status and survival in bilateral breast cancer (SEER data)
http://www.thebreastonline.com/article/S0960-9776(14)00220-3/abstract
After breast cancer diagnosis, risk of thyroid cancer goes up (SEER data)
http://www.medicalnewstoday.com/releases/290575.php?tw
Survival benefit from adjuvant RT in minor salivary gland tumors (SEER data)
http://www.oraloncology.com/article/S1368-8375(15)00127-X/abstract
Intermediate and high-risk prostate cancers on rise since PSA screening changes (NODA data)
http://www.asco.org/press-center/early-evidence-increase-higher-risk-prostate-cancers-2011-2013
Resources
250 Years of Advances Against Cancer (timeline)
http://www.cancer.gov/researchandfunding/progress/250-yearsadvances?utm_content=sf36598755&utm_medium=spredfast&utm_source=twitter&utm_campaign=N
ational+Cancer+Institute&cid=sf36598755
Early vocal cord cancer treatment options – laser vs. RT
http://bastianmedicalmedia.com/early-vocal-fold-cancer-remove-laser-radiate/
Colon cancer Infographic
http://www.cdc.gov/cancer/colorectal/basic_info/screening/infographic.htm
Tumor Location Portends CRC Survival
http://dx.doi.org/doi:10.1093/jnci/dju427
New Oncology Drugs Approved in 2014
Solid Tumors
http://www.practiceupdate.com/c/21002/3/0/?elsca1=emc_enews_top10&elsca2=email&elsca3=practiceupdate_onc&elsca4=oncology&elsca5=newsletter&rid=NTU2MjE4MT
E1NjYS1&lid=10332481
Hematologic disease
http://www.practiceupdate.com/c/21003/2/1/?elsca1=emc_enews_dailydigest&elsca2=email&elsca3=practiceupdate_onc&elsca4=oncology&elsca5=newsletter&rid=NTU2MjE4
MTE1NjYS1&lid=10332481
Ki-67 predicts CNS relapse in mantle cell lymphoma
http://annonc.oxfordjournals.org/content/early/2015/02/22/annonc.mdv074.abstract
Bladder cancer “no longer one single disease”
http://www.practiceupdate.com/c/22549/2/1/?elsca1=emc_enews_dailydigest&elsca2=email&elsca3=practiceupdate_onc&elsca4=oncology&elsca5=newsletter&rid=NTU2MjE4
MTE1NjYS1&lid=10332481
Targeting gastric cancer
http://www.curetoday.com/articles/targeting-gastric-cancer-recent-advances-generate-fresh-hopesafter-many-frustrations/1
Can B-ALL cells be reprogrammed to become harmless?
http://www.medicalnewstoday.com/articles/291115.php?tw
Predicting cancers
http://www.medicalnewstoday.com/releases/291020.php?tw
Tobacco epidemic Atlas
http://www.tobaccoatlas.org/
Use of tampons in endometrial cancer screening
http://www.medicalnewstoday.com/releases/291420.php?tw
Thanks again for all you do!
Nancy H. Rold, CTR
Operations Manager
Missouri Cancer Registry and Research Center